Watson Completes Actavis Acquisition

05-Nov-2012 - Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded the ...

Actavis acquires PharmaPack International

06-Dec-2011 - Actavis Group has acquired 100% of the shares in PharmaPack International B.V. for an undisclosed amount. PharmaPack is based in Zoetermeer, the Netherlands, and is a specialist in packaging pharmaceutical as well as biotechnological products. The company has extensive experience with product, ...

Actavis opens new headquarters in Zug, Switzerland

11-May-2011 - Actavis Group formally opened its new management offices in Zug, Switzerland. At a press conference to mark the opening of the new headquarters, CEO Claudio Albrecht stated that the generic industry "needs to change." Payors, he said, need modern approaches to cope with exploding health care ...

Actavis expands the world's only pharmaceutical manufacturing facility completely powered by renewable energy

Zero carbon footprint for tablet manufacturing and packaging

18-Jan-2011 - Actavis Group formally opened a new expansion to its pharmaceutical manufacturing site in Iceland. Powered solely by geothermal energy, giving it a zero carbon footprint for tablet manufacturing and packaging, the site uses no fossil fuels. The facility is fully accredited to supply the EU ...

Actavis plans to enter into Biosimilars

09-Sep-2010 - Actavis Group announced that it plans to enter into the field of biosimilars. Dr. Claudio Albrecht CEO of Actavis commented on the upcoming due diligence on Biopartners in Switzerland: “By entering into Biosimilars the generic companies gain access to a portfolio that requires a new approach to ...

Actavis appoints Claudio Albrecht CEO

24-Jun-2010 - Actavis Group announced the appointment of former Ratiopharm leader Dr. Claudio Albrecht as its new CEO. Dr. Claudio Albrecht has been appointed as CEO of Actavis, with immediate effect. He has over 20 years of experience in the generics industry, having started his career with Sandoz in 1987 ...

Actavis divests its distribution business in Bulgaria

11-Mar-2010 - Actavis has announced the divestment of its Bulgarian distribution company, Higia EAD, to a local private investor, Rossitsa Veselinova Velikova. This decision is a result of the detailed business review conducted on global and local level in 2009. Actavis continues to focus its efforts on its ...

Actavis expands manufacturing site in Iceland

Production at Actavis Hafnarfjordur site, Iceland

10-Feb-2010 - Actavis has announced plans to expand its manufacturing site in Iceland, increasing capacity at the site by 50%. Fifty new jobs will be created as a result. The Hafnarfjordur, Iceland manufacturing site exports 95% of its products. After expansion the SOD-site‘s capacity will be about 1.5 ...

Actavis acquires Kéri Pharma Generics

05-Oct-2005 - Actavis Group announced that it has acquired the generic business of the Hungarian pharmaceutical company, Kéri Pharma. Financial details were not disclosed. Kéri Pharma was founded in 1991 and specialises in the development, sales and marketing of generic pharmaceuticals in the central eastern ...

Actavis to acquire US generics company Amide

24-May-2005 - Actavis Group, the international generic pharmaceuticals company, and Amide Pharmaceutical, Inc., a privately owned US generic pharmaceuticals company, announced that Actavis has reached an agreement to acquire Amide for an initial gross consideration of US$500 million in cash with up to an ...